Written by the Nuvirox Research Team
Key points
- In mice, boosting NAD+ with nicotinamide riboside prevents and even reverses features of noise-induced and age-related hearing loss.
- There are, as of this writing, no published human trials testing NAD+ precursors for hearing preservation or restoration.
- Age-related hearing loss currently has no approved preventive drug therapy, which is exactly why this research area is being watched closely.
Short answer: the animal data is some of the more compelling NAD+ research out there, but it hasn't been tested in people yet. If you're hoping for a human-proven hearing supplement, this isn't it — but it's a legitimately active and interesting research thread worth understanding.
Why would NAD+ matter for hearing?
The sensory hair cells in your cochlea are metabolically demanding and essentially irreplaceable — once damaged by noise, aging, or certain medications, they don't regenerate. Their function depends heavily on mitochondrial energy production and on NAD+-dependent proteins like SIRT3, which helps protect cells from the oxidative stress that noise exposure and aging both generate. Both noise-induced hearing loss and age-related hearing loss (ARHL) are associated with declining NAD+ levels in cochlear tissue.
What does the evidence actually show?
A 2014 Cell Metabolism study first showed that activating SIRT3 with nicotinamide riboside protects mice from noise-induced hearing loss by preserving the "ribbon synapses" that connect hair cells to auditory neurons. Follow-up research extended this: NR administration prevented progression of age-related hearing loss in two different wild-type mouse strains, and a related NAD+ precursor prevented hearing loss in a mouse model of Cockayne syndrome, a rare premature-aging disorder with profound hearing loss. Newer work with nicotinamide mononucleotide (NMN) shows similar protection against ARHL progression in mice.
Study snapshot: NR and age-related hearing loss (mouse model)
| Design | Controlled animal study, two mouse strains |
| Intervention | Long-term oral nicotinamide riboside |
| Comparator | Untreated wild-type mice, same strains |
| Finding | NR administration prevented progression of age-related hearing loss |
| Caveat | Mouse cochlea, not human; no human trial yet |
The honest counterweight
Every single piece of positive evidence here comes from rodent models. The researchers behind the most recent NMN hearing study explicitly note that age-related hearing loss "has no approved measures for preventing or treating this debilitating condition" in humans — which is precisely why animal researchers are excited about this pathway, but it also means nobody has shown yet that an oral NAD+ precursor supplement measurably slows hearing decline in a person. Mouse cochlear biology and human cochlear biology overlap substantially, but dosing, bioavailability to the inner ear, and real-world timelines for hearing loss are all open questions.
When to see a doctor
If you're experiencing hearing changes, ringing in the ears, or sudden hearing loss (especially sudden loss in one ear), see an audiologist or ENT promptly — sudden hearing loss in particular is time-sensitive and treatable if caught early, and no supplement is a substitute for that evaluation.
What's actually proven to protect hearing today
Hearing protection (earplugs or earmuffs) around loud noise, limiting headphone volume and duration, and managing cardiovascular risk factors (which affect blood flow to the inner ear) remain the best-evidenced ways to protect hearing over time. Routine audiograms as you age can catch changes early, when hearing aids and other interventions are most effective.
How does hearing research fit with other NAD+ and aging findings?
Age-related hearing loss is often discussed alongside other age-related sensory declines in NAD+ research, and it fits the broader pattern documented in our overview of whether NAD+ actually declines with age — cochlear tissue appears to follow the same general trajectory as other metabolically demanding tissues. There's also a parallel worth knowing about in a different sensory system: research on NAD+ and tinnitus similarly finds mostly hearing-related mechanistic connections without much direct human trial data yet, and our page on NAD+ and eye health covers a comparable pattern in a different sensory organ.
One more mechanistic detail worth understanding: the mouse hearing-loss research specifically implicates SIRT3, a mitochondrial sirtuin that depends on NAD+ availability, as the key protective mechanism. This is a slightly different downstream pathway than the SIRT1-focused research that dominates most other NAD+ and aging studies, which may partly explain why hearing researchers are optimistic about translating animal findings, even though the translation hasn't happened yet.
For context on timeline: the foundational SIRT3/noise-induced hearing loss study was published in 2014, and the age-related hearing loss follow-up work has continued through 2023-2025, meaning this research area has had roughly a decade to produce a human trial and hasn't yet. That's not necessarily a red flag — audiology trials are inherently slow, since hearing loss progression is measured over years — but it's a useful data point when judging how far along this research really is.
If you're weighing whether to try an NAD+ precursor supplement for general wellness reasons while this research matures, it's worth knowing that the doses used in the mouse hearing studies don't map directly onto human supplement doses in a simple way, since interspecies dose scaling for oral supplements is complex and hasn't been specifically worked out for cochlear tissue. In the meantime, the practical hearing-protection steps below have decades of direct human evidence behind them, which is a meaningfully stronger footing to stand on.
It's also worth knowing that hearing loss has multiple distinct causes beyond noise and aging, including ototoxic medications, genetic factors, and vascular conditions, meaning even a future positive human trial on NAD+ precursors would likely apply to some causes of hearing loss more than others.
Until human data exists, hearing protection remains the most reliable, best-evidenced lever you actually control day to day.
Regular audiograms remain the best way to catch changes early enough to act on them.
Frequently asked questions
Can I take NAD+ supplements to protect my hearing?
There's no human trial evidence that oral NAD+ precursors protect hearing. The supporting research so far is entirely in mice.
Why hasn't this been tested in humans yet?
It's a newer research area (the key mouse hearing studies are from roughly 2014-2025), and human hearing-outcome trials are long, expensive, and require large sample sizes since hearing loss progresses slowly.
Is there anything proven to reverse hearing loss?
Cochlear damage from noise or aging is generally not reversible with current medicine; hearing aids and cochlear implants address function, and prevention remains the most reliable lever.
From Nuvirox
Why we formulated NAD+ Restore
NAD+ Restore isn't formulated to address this specific condition, but if you're also interested in general cellular energy and healthy-aging support, here's what's in it.
- 500 mg Nicotinamide Riboside Chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials
- 150 mg trans-resveratrol (Japanese Knotweed) + 50 mg quercetin (Sophora japonica) — polyphenols studied alongside NAD+ pathways for cellular health support
- 10 mg galactomannans from fenugreek — to support absorption
- 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should
The bottom line: the NAD+-and-hearing story is one of the more promising areas of NAD+ animal research, precisely because current human treatment options for age-related hearing loss are so limited. But "promising in mice" and "proven in people" are very different claims — protect your ears the old-fashioned way in the meantime.
References
- Brown KD, et al. Activation of SIRT3 by the NAD+ precursor nicotinamide riboside protects from noise-induced hearing loss. Cell Metab. 2014;20(6):1059-1068.
- Long-term NAD+ supplementation prevents the progression of age-related hearing loss in mice. PMID: 37395319.
- Short-term NAD+ supplementation prevents hearing loss in mouse models of Cockayne syndrome. npj Aging. 2020.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.